AbbVie Inc. (NYSE:ABBV) was the target of some unusual options trading on Wednesday. Stock investors purchased 278 put options on the company. This represents an increase of 121% compared to the average volume of 126 put options.

AbbVie (ABBV) opened at $92.31 on Friday. The company has a quick ratio of 1.25, a current ratio of 1.38 and a debt-to-equity ratio of 5.63. The company has a market cap of $145.09 billion, a price-to-earnings ratio of 17.14, a PEG ratio of 1.24 and a beta of 1.51.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.39 by $0.02. The business had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. AbbVie had a return on equity of 164.66% and a net margin of 24.38%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the business posted $1.21 EPS. analysts expect that AbbVie will post 5.55 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is currently 62.29%.

A number of equities research analysts have issued reports on the company. SunTrust Banks, Inc. restated a “buy” rating on shares of AbbVie in a research report on Monday, October 30th. Piper Jaffray Companies increased their price target on AbbVie to $115.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Barclays PLC reiterated a “hold” rating and issued a $68.00 price target on shares of AbbVie in a report on Thursday, September 28th. Evercore ISI reiterated an “outperform” rating and issued a $100.00 price target (up from $95.00) on shares of AbbVie in a report on Saturday, September 30th. Finally, Leerink Swann reduced their price target on AbbVie from $108.00 to $107.00 and set an “outperform” rating on the stock in a report on Monday, October 30th. Eight equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. AbbVie presently has a consensus rating of “Buy” and an average target price of $93.68.

In other AbbVie news, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $90.55, for a total transaction of $1,657,065.00. Following the sale, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Robert A. Michael sold 6,699 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $88.00, for a total value of $589,512.00. Following the sale, the vice president now owns 10,007 shares in the company, valued at $880,616. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 226,430 shares of company stock worth $16,664,544. Company insiders own 0.23% of the company’s stock.

Several institutional investors have recently made changes to their positions in ABBV. Bristlecone Advisors LLC acquired a new stake in AbbVie in the 3rd quarter worth about $113,000. Acropolis Investment Management LLC acquired a new stake in AbbVie in the 2nd quarter worth about $106,000. Ffcm LLC boosted its holdings in AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock worth $111,000 after buying an additional 963 shares during the last quarter. Hudock Capital Group LLC boosted its holdings in AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock worth $111,000 after buying an additional 806 shares during the last quarter. Finally, Hershey Trust Co. acquired a new stake in AbbVie in the 3rd quarter worth about $139,000. Hedge funds and other institutional investors own 68.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Investors Purchase Large Volume of Put Options on AbbVie (ABBV)” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/04/investors-purchase-large-volume-of-put-options-on-abbvie-abbv.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.